Our study shows that TGF-β1 stimulates ERK and AKT signaling channels and promotes renal tubular interstitial fibrosis, and anlotinib is used to reduce the inflammatory response, delay EMT, and improve renal fibrosis by inhibiting TGF-β1. The gene discussed is TGFB1; the disease is renal fibrosis.